CIK 0000315545 · Non-accelerated filer<br>Smaller reporting company
PROVECTUS BIOPHARMACEUTICALS, INC.
Sign in to watch- Ticker
- PVCT
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 900031917
- Phone
- (866) 594-5999
- Business address
- 800 S. GAY STREET, SUITE 1610, KNOXVILLE, TN, 37929
- Former names
- PROVECTUS PHARMACEUTICALS INC, PROVECTUS PHARMACEUTICAL INC, ZAMAGE DIGITAL IMAGING INC, SPM GROUP INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-10-16 | Pershing Edward CEO | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2025-10-16 | Pershing Edward CEO | Option exercise · Series D-1 Convertible Preferred Stock | +18,880 | 2,503,379 | ||
| 2025-10-10 | Pershing Edward CEO | Grant or award · 8% Unsecured Convertible Promissory Note | +0 | |||
| 2025-10-03 | Pershing Edward CEO | Grant or award · 8% Unsecured Convertible Promissory Note | +0 | |||
| 2025-09-30 | Pershing Edward CEO | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2025-09-30 | Pershing Edward CEO | Option exercise · Series D-1 Convertible Preferred Stock | +66,052 | 2,484,499 | ||
| 2025-09-19 | Pershing Edward CEO | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2025-09-19 | Pershing Edward CEO | Option exercise · Series D-1 Convertible Preferred Stock | +37,760 | 2,418,447 | ||
| 2025-09-18 | Pershing Edward CEO | Grant or award · 8% Unsecured Convertible Promissory Note | +0 | |||
| 2025-09-11 | Pershing Edward CEO | Grant or award · 8% Unsecured Convertible Promissory Note | +0 | |||
| 2025-09-04 | Pershing Edward CEO | Grant or award · 8% Unsecured Convertible Promissory Note | +0 | |||
| 2025-08-29 | Pershing Edward CEO | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2025-08-29 | Pershing Edward CEO | Option exercise · Series D-1 Convertible Preferred Stock | +28,320 | 2,380,687 | ||
| 2025-08-26 | Pershing Edward CEO | Grant or award · 8% Unsecured Convertible Promissory Note | +0 | |||
| 2025-08-22 | Pershing Edward CEO | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2025-08-22 | Pershing Edward CEO | Option exercise · Series D-1 Convertible Preferred Stock | +37,760 | 2,352,367 | ||
| 2025-08-08 | Pershing Edward CEO | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2025-08-08 | Pershing Edward CEO | Option exercise · Series D-1 Convertible Preferred Stock | +18,880 | 2,314,607 | ||
| 2025-07-18 | Pershing Edward CEO | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2025-07-18 | Pershing Edward CEO | Option exercise · Series D-1 Convertible Preferred Stock | +62,303 | 2,295,727 |
Page 4 of 8 · 143 trades